• Evogene announced acute graft-versus-host disease as the target for its internal AI-driven drug discovery program, focusing on patients unresponsive to steroids.
• Reported discovery-stage findings showed promising potency, selectivity and safety-related profiles; lead candidates are advancing toward studies supporting an investigational new drug application.
• The program targets a potential multibillion-dollar market where ruxolitinib remains the only approved second-line therapy.
• The disease affects approximately 30%-40% of stem cell transplant recipients; mortality among steroid-refractory patients can reach 50%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610280830PR_NEWS_USPR_____IO83185) on October 28, 2026, and is solely responsible for the information contained therein.